首页> 外文期刊>Biopolymers: Original Research on Biomolecules and Biomolecular Assemblies >Combined Fourier transform infrared and Raman spectroscopic identification approach for identification of multidrug resistance phenotype in cancer cell lines
【24h】

Combined Fourier transform infrared and Raman spectroscopic identification approach for identification of multidrug resistance phenotype in cancer cell lines

机译:傅里叶变换红外和拉曼光谱相结合的鉴定方法用于癌细胞株多药耐药表型的鉴定

获取原文
获取原文并翻译 | 示例
           

摘要

Cancer cells escape cytotoxic effects of anticancer drugs by a process known as multidrug resistance (MDR). Identification of cell status by less time-consuming methods can be extremely useful in patient management and treatment. This study aims at evaluating the potentials of vibrational spectroscopic methods to perform cell typing and to differentiate between sensitive and resistant human cancer cell lines, in particular those that exhibit the MDR phenotype. Micro-Raman and Fourier transform infrared (FTIR) spectra have been acquired from the sensitive promyelocytic HL60 leukemia cell line and two of its subclones resistant to doxorubicin (HL60/DOX) and daunorubicin (HL60/ DNR), and from the sensitive MCF7 breast cancer cell line and its MDR counterpart resistant to verapamil (MCF7/VP). Principal components analysis (PCA) was employed for spectral comparison and classification. Our data show that cell typing was feasible with both methods, giving two distinct clusters for HL60- and MCF7-sensitive cells. In addition, phenotyping of HL60 cells, i.e., discriminating between the sensitive and MDR phenotypes, was attempted by both methods. FTIR could not only delineate between the sensitive and resistant HL60 cells, but also gave two distinct clusters for the resistant cells, which required a two-step procedure with Raman spectra. In the case of MCF7 cell lines, both the sensitive and resistant phenotypes could be differentiated very efficiently by PCA analysis of their FTIR and Raman point spectra. These results indicate the prospective applicability of FTIR and micro-Raman approaches in the differentiation of cell types as well as characterization of the cell status, such as the MDR phenotype exhibited in resistant leukemia cell lines like HL60 and MCF7. (c) 2006 Wiley Periodicals, Inc.
机译:癌细胞通过称为多药耐药性(MDR)的过程逃脱了抗癌药的细胞毒性作用。通过较少耗时的方法鉴定细胞状态在患者管理和治疗中非常有用。这项研究旨在评估振动光谱法进行细胞分型并区分敏感和耐药人类癌细胞系(尤其是表现出MDR表型的癌细胞系)的潜力。已从敏感的早幼粒细胞HL60白血病细胞系及其对阿霉素(HL60 / DOX)和柔红霉素(HL60 / DNR)耐药的两个亚克隆和敏感的MCF7乳腺癌中获得了显微拉曼光谱和傅里叶变换红外光谱(FTIR)细胞系及其对维拉帕米(MCF7 / VP)具有抗药性的MDR对应物。主成分分析(PCA)用于光谱比较和分类。我们的数据表明,用两种方法进行细胞分型都是可行的,从而为HL60和MCF7敏感细胞提供了两个不同的簇。另外,两种方法都试图对HL60细胞进行表型化,即区分敏感表型和MDR表型。 FTIR不仅可以区分敏感和耐药的HL60细胞,还可以为耐药细胞提供两个不同的簇,这需要使用拉曼光谱进行两步操作。对于MCF7细胞系,通过PCA分析其FTIR和拉曼点光谱,可以非常有效地区分敏感和耐药表型。这些结果表明FTIR和显微拉曼方法在细胞类型的分化以及细胞状态的表征方面具有前瞻性的应用,例如在耐药性白血病细胞株(如HL60和MCF7)中表现出的MDR表型。 (c)2006年Wiley Periodicals,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号